Cygnus Healthcare Specialities Private Limited, Mumbai

Packaging Size	25 ml
Dose	25mg/ml
Form	Injection
Packaging Type	Bottle
Prescription/Non prescription	Prescription

Compositions:

• Each ml contains Aciclovir BP 25 mg

Pharmacological classification & ATC Classification:

• J05AB01 - aciclovir; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections. 

Pharmacology:

• Activity against HSV types I and II and varicella-zoster virus is due to intracellular conversion of aciclovir to the monophosphate by viral thymidine kinase with subsequent conversion to the diphosphate and active triphosphate by cellular enzymes. This active form inhibits viral DNA synthesis and replication by interfering with viral DNA polymerase enzyme and being incorporated into viral DNA.
• Absorption: 15-30% is absorbed from the GI tract (oral), slightly absorbed from the skin (topical), absorbed from the eye (ophthalmic).
• Distribution: CSF (50% of conc is similar to those in plasma); crosses the placenta and enters breast milk (concentrations 3 times higher than in maternal serum). Protein-binding: 9-33%. Excretion: Via kidney by glomerular filtration and tubular secretion (14% as unchanged), via faeces (2%); elimination half-life: 2-3 hr (normal renal function), 19.5% (anuric patients), 5-7% (haemodialysis patients).

Indications:

• Aciclovir indicated in:
• Mucocutaneous herpes simplex in immunocompromised patients
• Herpes simplex encephalitis
• Genital herpes
• Neonatal herpes simplex virus infections
• Herpes zoster in immunocompromised patients

Dosage & administration:

• Intravenous
• Mucocutaneous herpes simplex in immunocompromised patients
• Adult : 5 mg/kg every 8 hr for 7 days. Dose to be given as IV infusion over 1 hr. 
• Child : 10 mg/kg every 8 hr for 7 days.

Renal Impairment:

• Peritoneal dialysis: Half the usual dose once daily. Haemodialysis: Half the usual dose every 24 hr and an additional half-dose after haemodialysis.
• CrCl (ml/min) Dosage Recommendation
• 25-50 Increase dose interval to 12 hr.
• 10-25 Increase dose interval to 24 hr.

Strength	1000 mg
Pack Size	100 ml
Pack Type	Bottle
Drug Composition	Paracetamol 1000mg
Brand	Cyparin
Usage/Application	Treat Pain and Reduce Fever
Prescription/Non-Prescription	Prescription

Description:

• Paracetamol solution for infusion is a clear and slightly yellowish solution. It contains 10mg/mL of paracetamol. Paracetamol is a white crystalline solid or powder chemically described as 4 - acetaminophen.

Clinical Pharmacology:

• Pharmacodynamics
• Paracetamol 10 mg/mL, solution for infusion provides onset of pain relief within 5 to 10 minutes after the start of administration. The peak analgesic effect is obtained in 1 hour and the duration of this effect is usually 4 to 6 hours. Paracetamol 10 mg/mL, solution for infusion reduces fever within 30 minutes after the start of administration with a duration of the antipyretic effect of at least 6 hours.

Pharmacokinetics:

• Adults
• Absorption: Paracetamol pharmacokinetics are linear after a single administration of up to 2 g and after repeated administration during 24 hours.

Distribution:

• The volume of distribution of paracetamol is approximately 1 L/kg.
• Paracetamol is not extensively bound to plasma proteins.
• Following infusion of 2g proparacetamol, (equivalent to 1g of paracetamol) significant concentrations of paracetamol (about 1.5 µg/mL) were observed in the cerebrospinal fluid 20 minutes after infusion.

Brand	Dexasone
Manufacturer	Cadila
Strength	4mg
Packaging Type	vial
Packaging Size	20ml
Usage/Application	Mild Covid 19, Rheumatic problems, Treat severe allergic, Gastrointestinal disease
Prescription/Non prescription	Prescription

Dexamethasone injection is used to treat severe allergic reactions. It is used in the management of certain types of edema (fluid retention and swelling; excess fluid held in body tissues,) gastrointestinal disease, and certain types of arthritis. Dexamethasone injection is also used for diagnostic testing.

Metronidazole Injection is used to treat Anaerobic bacterial infections, infections by Bacteroides fragilis. It is also used to tackle some infections by Fungi Bacteria, Eubacteria Clostridia, Anaerobic cocci, Gingivitis pericoronitis. It is also administered on patients before, during and after surgery.

Rare side effects include discomfort, nausea, gastro-intestinal disturbances.

Patients with treatment more than 10 days must be strictly monitored.

Check with your general physician regarding any allergies and pre existing conditions and administer Metronidazole Injection as per prescription. 

Strength	1000mg
Pack Size	100 ml
Pack Type	Vial
Drug Composition	Paracetamol 1000mg
Usage/Application	Treat Pain and Reduce Fever
Prescription/Non-Prescription	Prescription

We are the leading supplier of Paracetamol 1000mg/100ml Vial Injection providing it at best possible market price

Packaging Size	5000 IU
Manufacturer	SG Pharma Pvt Ltd
Brand	Asparaginase
Dosage Form	Single Use Vial
Prescription/Non prescription	Prescription
Form	Injection
Packaging Type	Bottle

Description

• Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid. It is used for the treatment of acute lymphoblastic leukemia (ALL)[1] and is also used in some mast cell tumor protocols. [2] Unlike other chemotherapy agents, it can be given as an intramuscular, subcutaneous, or intravenous injection without fear of tissue irritation.

Mechanism of action

• The rationale behind asparaginase is that it takes advantage of the fact that ALL leukemic cells are unable to synthesize the non-essential amino acid asparagine, whereas normal cells are able to make their own asparagine; thus leukemic cells require a high amount of asparagine. These leukemic cells depend on circulating asparagine. Asparaginase, however, catalyzes the conversion of L-asparagine to aspartic acid and ammonia. This deprives the leukemic cell of circulating asparagine.

Side effects

• The main side effect is an allergic or hypersensitivity reaction; anaphylaxis is a possibility.

Other Details:-

• Asparaginase has also been associated with pancreatitis. Additionally, it can also be associated with a coagulopathy as it decreases protein synthesis, including synthesis of coagulation factors (eg progressive isolated decrease of fibrinogen) and anticoagulant factor (generally antithrombin III; sometimes protein C & S as well), leading to bleeding or thrombotic events such as stroke.
• Lyophilized For I.M./I.V. Use Only To be sold under medical keep out of reach of children

Packaging Size	Box
Brand	Onconasa
Prescription/Non prescription	Prescription
Form	Injection
Asparginase	5000 IU
Dose	5 mg

We are leading manufacturer and exporter of Asparaginase For Injection and our product is made up of good quality.

Compositions:

• Each vial contains Asparginase 5000 IU or 10000 IU

Pharmacological classification & ATC Classification:

• L01XX02 - asparaginase; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.

Pharmacology:

• Asparaginase interferes with malignant cell growth by breaking down asparagine to aspartic acid and ammonia as leukemic cells are unable to synthesize asparagine and depend on the exogenous source of asparagine for survival. It acts on the G1 phase of the cell cycle.
• Distribution: Distributed at lymph; does not penetrate the CSF.
• Excretion: Urine (small amounts). Elimination half-life: 8-30 hr (IV); 49 hr (IM).

Indications:

• Asparaginase indicated in Induction of remission in acute lymphoblastic leukemia

Dosage & administration:

• Parenteral
• Induction of remission in acute lymphoblastic leukemia
• Adult: 1000 units/kg/day via IV injection for 10 days after treatment with vincristine and prednisone or. Alternatively, 6000 units/m2 via IM injection, given every 3rd days for 9 doses during treatment with vincristine and prednisone or. As monotherapy: 200 units/kg/day via IV and for 28 days. IV injection to be given over at least 30 min in a running infusion of normal saline or glucose 5%. For IM admin, no more than 2 ml of a solution in normal saline should be injected at a single site.
• Child: As monotherapy: 200 units/kg/day via IV injection for 28 days, to be given over at least 30 min in a running infusion of normal saline or glucose 5%.

Special Populations:

• NOTE: When administered IV, the drug should be given over 30 min along with NS or 5% dextrose.
• Incompatibility: Incompatible with rubber and should not be mixed with other drugs.

Contraindications:

• Pancreatitis, hypersensitivity. Pregnancy.

Precautions:

• Should be used after skin testing, in a hospital setting. Liver disease, frequently blood count monitoring. Lactation.

Side Effects:

• Chills, pyrexia, liver disorders. Hyperammonaemia, a decrease of fibrinogen and clotting factors, alteration in blood lipids and cholesterol, hypoalbuminemia, uremia, renal failure (occasional). Hyperglycemia. Nausea, vomiting, anorexia, weight loss. CNS disturbances including depression, coma, hallucinations, Parkinson-like syndrome. Marked leucopenia, transient bone-marrow depression.
• Potentially Fatal: Acute anaphylaxis; fatal hyperthermia; pancreatitis; ketoacidosis.

Drug Interactions:

• The activity of methotrexate may be reduced if L-asparaginase is given beforehand.
• Potentially Fatal: IV admin of asparaginase may increase vincristine neurotoxicity.

Pregnancy & Lactation:

• Category C: Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.

Storage:

• Parenteral: Refrigerate at 2-8°C.

Packing presentations:

• (Also can be packed according to customer’s requirement)
• Vials containing lyophilized powder Each vial contains Asparaginase 5000 IU/ 10000 IU

Packaging Size	10x1 ml Ampoules
Brand	Largnak-AQ
Prescription/Non prescription	Prescription
Form	Injection
Dose	25.0 mg
Packaging Type	Box
Diclofenac Sodium BP	25.0 mg

Indications :

• Lekalza Injection is indicated for the treatment of the signs and symptoms of acute and chronic rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Painful post-traumatic and post-operative inflammation and swelling. pain following dental surgery. Acute attacks of gout. Painful gynecological conditions.

Dosage and direction for use :

• The recommended doses of the diclofenac injection is 1 ampoule (75 mg) once daily or, if required in severe cases twice daily, injected deep intraglutealy.
• Diclofenac injection for intramuscular and should not be mixed with other injection sole Lekalza Injection should not be given more than 2 days.Lekalza Injection are not recommended for use in children.
• OR As directed by the physician

Contraindications :

• Lekalza injections are contraindicated in the patient who is hypersensitive to it, and in whom drugs like and other NSAIDs precipitate attacks of asthma, urticaria or acute rheumatic. It should be given to patients with peptic ulcer.

Side effects :

• Perforation of gastriculcers.
• GIT haemorrhage, blood dyscriasias and anaphylaxis (rare)
• Others: G.I. disturbances, headache, dizziness. rash, pruritus, peripheral oedema.
• G.I.Bleeding: Pepticulcer, abnormalities of liver and kidney function.

Drug Interaction :

• Deterioration in renal function has been attributed to the concomitant use of Diclofenac and triamterene or cyclosporin. As with other NSAIDs, Diclofenac Sodium is likely to inhibit the activity of the diuretics. Concomitant treatment with potassium diuretics may increase the serum potassium levels. Plasma concentrations of lithium or digoxin are increased when these drugs are given together with Diclofenac Sodium.
• Aqueous base injection 

Brand	Aminophylline
Manufacturer	Nimed
Prescription/Non prescription	Prescription
Medicine Type	Allopathic
Packaging Size	2 x 5 ampoules
Packaging Type	Glass Bottle
Storage Temeprature	Below 25 Degree C
Dose	25mg/ml

Compositions:

• Each ml contains Aminophylline BP 25 mg

Pharmacological classification & ATC Classification:

• R03DA05 - aminophylline ; Belongs to the class of xanthines. Used in the systemic treatment of obstructive airway s.

Pharmacology:

• Aminophylline is a combination of theophylline and ethylenediamine. Ethylenediamine is inactive; it increases the solubility of theophylline in water. Theophylline relaxes bronchial smooth muscle. Suggested mechanisms are an increase in intracellular cAMP through inhibition of phosphodiesterase; receptor antagonism, prostaglandin antagonism and effects on intracellular calcium.
• Absorption: Rate of absorption delayed by food.
• Distribution: Crosses the placenta and enters breast milk.
• Metabolism: Undergoes hepatic metabolism.
• Excretion: Via urine.

Indications:

• Aminophylline is a complex of theophylline and ethylenediamine and is given for its theophylline activity to relax smooth muscle and to relieve bronchial spasm.
• Aminophylline Injection is indicated for relief of bronchospasm associated with asthma and in chronic obstructive pulmonary .

Dosage & administration:

• Intravenous
• Acute severe bronchospasm
• Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min.
• Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
• Elderly: Dose reduction may be ncessary.
• Hepatic impairment: Dose reduction may be ncessary.
• Special Populations: Reduce maintenance dose in patients with cor pulmonale, heart failure or liver and in elderly. Increase maintenance dose for smokers.
• Incompatibility: Incompatible with metals.

Contraindications:

• Aminophylline injection should not be used in patients hypersensitive to ethylenediamine or those allergic to the theophyllines, caffeine or theobromine.
• Aminophylline should not be administered concomitantly with other xanthine drugs. When therapeutic doses of Aminophylline and/or theophylline are administered simultaneously by more than one route or in more than one preparation, the hazard of serious toxicity is increased.
• The use of Aminophylline IV in children under 6 months of age is not generally recommended.
• The use of Aminophylline is contra-indicated in patients with acute porphyria.

Overdosage:

• Symptoms may include agitated maniacal behavior, frequent vomiting, extreme thirst, slight fever, tinnitus, palpitation and arrhythmias. Treatment is usually supportive and withdrawal of the drug. Restoration of fluid and electrolyte balance is necessary.

Precautions:

• Neonates, elderly, lactation, pregnancy, cardiac/hepatic s, peptic ulceration, hyperthyroidism, hypertension, epilepsy, heart failure, chronic alcoholism, acute febrile illness.

Side Effects:

• Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness; tremor, palpitations.
• Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV injection.
• Pregnancy & Lactation:Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Manufacturer	Baxter Healthcare Corporation
Brand	Carboplatin
Dose	450 mg
Packaging Size	45 ml
Packaging Type	Bottle
Form	Injection

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers). It was introduced in the late 1980s and has since gained popularity in clinical treatment due to its vastly reduced side-effects compared to its parent compound cisplatin. Cisplatin and carboplatin, as well as oxaliplatin, interact with DNA, akin to the mechanism of alkylating agents.2] Carboplatin differs from cisplatin in that it has a bidentate dicarboxylate (CBDCA) ligand as its leaving group instead of the more labile chloride ligands. 


Other Details:-

• NDC 25021-202-45
• Rx Only 
• Must Be Diluted
• For Iv  Infusion 
• Or Direct Injection Use 

Packaging Size	1 single dose vial
Brand	Cyclophosphamide
Manufacturer	Baxter Healthcare Corporation
Prescription/Non prescription	Prescription
Dose	500 mg
Form	Injection

Description

• Cyclophosphamide is a nitrogen mustard alkylating agent, from the oxazophorines group.
• An alkylating agent adds an alkyl group (CnH2n+1) to DNA. It attaches the alkyl group to the guanine base of DNA, at the number 7 nitrogen atom of the imidazole ring.
• It is used to treat various types of cancer and some autoimmune disorders. It is a "prodrug"; it is converted in the liver to active forms that have chemotherapeutic activity.
• Uses - The main use of cyclophosphamide is together with other chemotherapy agents in the treatment of lymphomas, some forms of leukemia and some solid tumors. It is a chemotherapy drug that works by slowing or stopping cell growth. Cyclophosphamide also decreases the immune system's response to various diseases and conditions. Therefore, it has been used in various non-neoplastic autoimmune diseases where disease-modifying antirheumatic drugs have been ineffective.

Mode of action:

• The main effect of cyclophosphamide is due to its metabolite phosphoramide mustard. This metabolite is only formed in cells that have low levels of ALDH.
• Phosphoramide mustard forms DNA crosslinks between (interstrand cross-linkages) and within (intrastrand cross-linkages) DNA strands at guanine N-7 positions. This leads to cell death.

Side-effects

• Many people taking cyclophosphamide do not have serious side effects. Side-effects include chemotherapy-induced nausea and vomiting (CINV), bone marrow suppression, stomach ache, diarrhea, darkening of the skin/nails, alopecia (hair loss) or thinning of hair, changes in color and texture of the hair, and lethargy. Hemorrhagic cystitis is a frequent complication, but this is prevented by adequate fluid intake and Mesna (sodium 2-mercaptoethane sulfonate). Mesna is a sulfhydryl donor and binds acrolein.

Other Details:-

• Ndc 10019-955-01
• Rx Only 
• Must Be Diluted
• For Iv  Infusion 
• Or Direct Injection Use 

Packaging Size	200 ml Rx only
Prescription/Non prescription	Prescription
Dose	200mg
Packaging Type	Bottle
Dose Form	Injection

Cisplatin is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumors. It was the first member of a class of anti-cancer drugs which now also includes carboplatin and oxaliplatin. These platinum complexes react in vivo, binding to and causing crosslinking of DNA which ultimately triggers apoptosis (programmed cell death).

Usage

• Cisplatin is administered intravenously as short-term infusion in physiological saline for treatment of solid malignancies.

Transplatin

• Transplatin, the trans stereoisomer of cisplatin, has formula trans-[PtCl2(NH3)2] and does not exhibit a comparably useful pharmacological effect. Its low activity is generally thought to be due to rapid deactivation of the drug before it can arrive at the DNA.[citation needed] It is toxic, and it is desirable to test batches of cis-platin for the absence of the trans isomer. In a procedure by Woollins et al., which is based on the classic 'Kurnakov test', thiourea reacts with the sample to give derivatives which can easily be separated and detected by HPLC.
• Cisplatin InjectionFor Intravenous Use  Multiple Dose Vial

Packaging Size	Bottle
Prescription/Non prescription	Prescription
Usage	Commercial
Packaging Type	Vial
Product Type	Finished Product
Form	Liquid
Dose Form	Injection

Customers can avail from us an extensive array of Powder Injections which is prepared from high-grade components as per the set industry norms.

Packaging Type	Vial
Usage	Hospital
Product Type	Finished Product
Dose Form	Injections
Medicine Type	Allopathic

We are leading manufacturer and exporter of Migraine Injections and our product is made up of good quality.

Packaging Size	5 ml
Manufacturer	Miracalus
Brand	Relbovin
Prescription/Non prescription	Prescription
Dose	5 mg
Form	Injection
Packaging Type	Bottle

We are leading manufacturer and exporter of Vinorelbine Injection and our product is made up of good quality.

Description

• Vinorelbine Tartrate Injection is for intravenous administration. Each vial contains vinorelbine tartrate equivalent to 10 mg (1-mL vial) or 50 mg (5-mL vial) vinorelbine in Water for Injection, USP. No preservatives or other additives are present. The aqueous solution is sterile and nonpyrogenic. Vinorelbine tartrate is a semi-synthetic vinca alkaloid with antitumor activity. The chemical name is 3’,4’-didehydro-4’-deoxy-C’-norvincaleukoblastine [R-(R*,R*)-2,3-dihydroxybutanedioate (1:2)(salt)]. Vinorelbine tartrate has the following structure.
• Vinorelbine tartrate is a white to yellow or light brown amorphous powder with the molecular formula C45H54N4O8·2C4H6O6 and molecular weight of 1079.12. The aqueous solubility is >1,000 mg/mL in distilled water.The pH of Vinorelbine Injection is approximately 3.5.

Clinical Pharmacology :

• Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. Unlike other vinca alkaloids, the catharanthine unit is the site of structural modification for vinorelbine. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin- dependent Ca++-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. In intact tectal plates from mouse embryos, vinorelbine, vincristine, and vinblastine inhibited mitotic microtubule formation at the same concentration (2 µM), inducing a blockade of cells at metaphase. Vincristine produced depolymerization of axonal microtubules at 5 µM, but vinblastine and vinorelbine did not have this effect until concentrations of 30 µM and 40 µM, respectively. These data suggest relative selectivity of vinorelbine for mitotic microtubules.

Indications And Usage :

• Vinorelbine is indicated as a single agent or in combination with for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Vinorelbine is indicated as a single agent or in combination with. In Stage III NSCLC, Vinorelbine is indicated in combination with.

Contraindications :

• Administration of Vinorelbine is contraindicated in patients with pretreatment granulocyte counts <1,000 cells/mm3

Warning :

• Vinorelbine should not be used in pregnancy,lactation and in pediatrics..

Packaging Size	1x6 Vial
Brand	Artemether
Manufacturer	Arrow Pharm Group
Prescription/Non prescription	Prescription
Dose/Strength	80 mg
Packing Type	Box

Atc Classification & Description:

• P01BE02 - ; Belongs to the class of artemisinin and derivative antimalarials. The chemical name of is (3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2benzodioxepine. is a white, crystalline powder that is freely soluble in acetone, soluble in methanol and ethanol, and practically insoluble in water. It has the empirical formula C16H26O5 with a molecular weight of 298.4.

Mechanism of Action:

• is a potent and rapidly acting blood schizontocide, which is highly efficacious in treating chloroquine-resistant falciparum malaria, and complicated falciparum malaria including cerebral malaria. Its quick onset of effect and high efficacy in bringing down the parasite load are the properties which make this drug a suitable therapeutic option against falciparum infection.
• Metabolism: Rapidly hydrolysed to the active metabolite dihydroartemisinin.
• Excretion: Elimination half-life: about 4-11 hr after IM or oral admin.

Therapeutic Indications:

• For the treatment of all kinds of malaria including the chloroquine-resistant P. falciparum malaria and the first aid of critical malaria.

Dosage and administration:

• The drug is used for intramuscular injection, five days course with the initial dose of 3.2mg/kg, followed by 1.6rng/kg for the following 4 days. The initial dose for adults is 160mg (2 ampoules), followed by 80mg (1 ampoule) every time from the 2" to 5th day. The dose for children or overweight patients should be decreased or increased on the basis of the individual weight or under the doctor's prescription.
• Administration For Children:
• For children, the dose should be chosen as follows:

Administration For Children:

• For children, the dose should be chosen as follows:
• Adverse Drug Reactions
• Mild GI disturbance, dizziness, tinnitus, reduction in reticulocyte and leucocyte counts, nausea, vomiting, abdominal pain, bradycardia, 1st-degree heart block, transient increase in serum transaminases.

Contra-Indication:

• is contra-indicated to those patients which have a history of hypersensitivity to .
• Precaution :
• Pregnancy:
• Pregnancy and lactation. Avoid concomitant use of drugs known to prolong QT interval or monitor such patients.
• Lactation:
• excretes into breast milk. It should not be taken by breast-feeding women.

Drug Interactions :

• causes QT prolongation in some patients. Thus concomitant use of erythromycin, , procainamide, quinidine, , amiodarone, bretylium, bepridil,, probucol, tricyclic antidepressants, s may be avoided.

Instructions :

• Each pack contains 10 ampoules of 80 mg/1ml.

Other Details:-

• Each 1 Ml Contains 
• Artemether Ip ...80 Mg
• Antimalarial
• 6 Ampoules +12 Alcoholic Swabs